These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 20858032)

  • 1. N-aryl pyrazoles, indazoles and azaindazoles as antagonists of CC chemokine receptor 1: patent cooperation treaty applications WO2010/036632, WO2009/134666 and WO2009/137338.
    Carter PH; Hynes J
    Expert Opin Ther Pat; 2010 Nov; 20(11):1609-18. PubMed ID: 20858032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl)ethanones as novel CCR1 antagonists.
    Pennell AM; Aggen JB; Sen S; Chen W; Xu Y; Sullivan E; Li L; Greenman K; Charvat T; Hansen D; Dairaghi DJ; Wright JJ; Zhang P
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1228-31. PubMed ID: 23374868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCR1 antagonists for the treatment of autoimmune diseases.
    Gladue RP; Zwillich SH; Clucas AT; Brown MF
    Curr Opin Investig Drugs; 2004 May; 5(5):499-504. PubMed ID: 15202722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spiroindenes and spiroindanes as antagonists of CC chemokine receptor 2: WO 2009023754.
    Carter PH
    Expert Opin Ther Pat; 2010 Feb; 20(2):283-9. PubMed ID: 20100008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel azaindazole CCR1 antagonist clinical candidates.
    Harcken C; Kuzmich D; Cook B; Mao C; Disalvo D; Razavi H; Swinamer A; Liu P; Zhang Q; Kukulka A; Skow D; Patel M; Patel M; Fletcher K; Sherry T; Joseph D; Smith D; Canfield M; Souza D; Bogdanffy M; Berg K; Brown M
    Bioorg Med Chem Lett; 2019 Feb; 29(3):441-448. PubMed ID: 30595446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemokine receptor antagonists: Part 1.
    Pease JE; Horuk R
    Expert Opin Ther Pat; 2009 Jan; 19(1):39-58. PubMed ID: 19441897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and optimization of pyrazole amides as antagonists of CCR1.
    Harcken C; Sarko C; Mao C; Lord J; Raudenbush B; Razavi H; Liu P; Swinamer A; Disalvo D; Lee T; Lin S; Kukulka A; Grbic H; Patel M; Patel M; Fletcher K; Joseph D; White D; Amodeo L; Berg K; Brown M; Thomson DS
    Bioorg Med Chem Lett; 2019 Feb; 29(3):435-440. PubMed ID: 30455146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent developments in CCR2 antagonists.
    Xia M; Sui Z
    Expert Opin Ther Pat; 2009 Mar; 19(3):295-303. PubMed ID: 19441905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel pyrrolidine ureas as C-C chemokine receptor 1 (CCR1) antagonists.
    Merritt JR; Liu J; Quadros E; Morris ML; Liu R; Zhang R; Jacob B; Postelnek J; Hicks CM; Chen W; Kimble EF; Rogers WL; O'Brien L; White N; Desai H; Bansal S; King G; Ohlmeyer MJ; Appell KC; Webb ML
    J Med Chem; 2009 Mar; 52(5):1295-301. PubMed ID: 19183043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCR1- and CCR5-mediated inactivation of leukocytes by a nonglycosaminoglycan (non-GAG)-binding variant of n-nonanoyl-CCL14 (NNY-CCL14).
    Gupta S; Rieder S; Richter R; Schulz-Maronde S; Manns J; Escher SE; Heitland A; Mack M; Forssmann WG; Elsner J; Forssmann U
    J Leukoc Biol; 2010 Aug; 88(2):383-92. PubMed ID: 20483925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico study of 1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl) ethanones derivatives as CCR1 antagonist: homology modeling, docking and 3D-QSAR approach.
    Balasubramanian PK; Balupuri A; Kothandan G; Cho SJ
    Bioorg Med Chem Lett; 2014 Feb; 24(3):928-33. PubMed ID: 24424131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCR1 chemokine receptor antagonist.
    Saeki T; Naya A
    Curr Pharm Des; 2003; 9(15):1201-8. PubMed ID: 12769747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical potential of chemokine receptor antagonists.
    Ribeiro S; Horuk R
    Pharmacol Ther; 2005 Jul; 107(1):44-58. PubMed ID: 15894378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of CCR1 antagonists for multiple myeloma.
    Karash AR; Gilchrist A
    Future Med Chem; 2011 Nov; 3(15):1889-908. PubMed ID: 22023033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3D-pharmacophere models for CC chemokine receptor 1 antagonists.
    Liu Y; Andre P; Wei J; Zhao K
    Med Chem; 2009 Jul; 5(4):318-24. PubMed ID: 19689388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCR1 antagonists in clinical development.
    Pease JE; Horuk R
    Expert Opin Investig Drugs; 2005 Jul; 14(7):785-96. PubMed ID: 16022568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AZD-4818, a chemokine CCR1 antagonist: WO2008103126 and WO2009011653.
    Norman P
    Expert Opin Ther Pat; 2009 Nov; 19(11):1629-33. PubMed ID: 19586423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BX-471 Berlex.
    Elices MJ
    Curr Opin Investig Drugs; 2002 Jun; 3(6):865-9. PubMed ID: 12137405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the chemokine network in renal inflammation.
    Eis V; Vielhauer V; Anders HJ
    Arch Immunol Ther Exp (Warsz); 2004; 52(3):164-72. PubMed ID: 15247883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel series of human CCR1 antagonists.
    Xie YF; Sircar I; Lake K; Komandla M; Ligsay K; Li J; Xu K; Parise J; Schneider L; Huang D; Liu J; Sakurai N; Barbosa M; Jack R
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2215-21. PubMed ID: 18329267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.